Hubei Biocause Heilen Pharmaceutical Co., Ltd.
301211.SZ · SHZ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | CN¥4,222,080 | CN¥4,330,726 | CN¥5,734,082 | CN¥6,223,682 |
| - Cash | CN¥543,140 | CN¥1,694,327 | CN¥1,858,089 | CN¥1,859,615 |
| + Debt | CN¥19,237 | CN¥5,155 | CN¥7,396 | CN¥30,260 |
| Enterprise Value | CN¥3,698,177 | CN¥2,641,555 | CN¥3,883,390 | CN¥4,394,327 |
| Revenue | CN¥445,864 | CN¥663,026 | CN¥514,912 | CN¥540,623 |
| % Growth | -32.8% | 28.8% | -4.8% | – |
| Gross Profit | CN¥128,591 | CN¥266,351 | CN¥148,694 | CN¥182,296 |
| % Margin | 28.8% | 40.2% | 28.9% | 33.7% |
| EBITDA | CN¥126,164 | CN¥225,152 | CN¥169,774 | CN¥158,925 |
| % Margin | 28.3% | 34% | 33% | 29.4% |
| Net Income | CN¥91,547 | CN¥176,116 | CN¥125,793 | CN¥121,649 |
| % Margin | 20.5% | 26.6% | 24.4% | 22.5% |
| EPS Diluted | 0.32 | 0.61 | 0.44 | 0.42 |
| % Growth | -47.5% | 38.6% | 4.8% | – |
| Operating Cash Flow | CN¥96,073 | CN¥137,063 | CN¥250,795 | CN¥123,984 |
| Capital Expenditures | -CN¥164,430 | -CN¥186,532 | -CN¥75,951 | -CN¥21,066 |
| Free Cash Flow | -CN¥68,356 | -CN¥49,468 | CN¥174,843 | CN¥102,918 |